HGH Fragment 176-191

HGH Fragment 176-191 refers to a short peptide corresponding to the C-terminal region of human growth hormone (the amino acids at positions 176 through 191 of the full hormone). It has been studied because researchers hypothesized that this segment might carry some of growth hormone's fat-metabolism activity while leaving aside the broader growth-promoting signaling of the intact hormone.

In experimental and wellness-oriented settings, the fragment is most often discussed in the context of body composition and fat metabolism. Claims found in marketing materials frequently extend well beyond what formal, high-quality clinical evidence supports, and its regulatory standing varies by region.

Proposed mechanisms for HGH Fragment 176-191 are drawn largely from preclinical work on the lipolytic (fat-breakdown) portion of the growth hormone molecule. High-level themes include:

• Engaging pathways involved in the breakdown of stored fat and energy expenditure

• A hypothesized separation of growth hormone's metabolic effects from its growth-promoting and IGF-1 signaling

• Acting without the same influence on IGF-1 or blood-sugar handling attributed to full-length growth hormone

Whether these mechanistic observations translate into meaningful, durable outcomes in humans remains an open research question rather than a settled fact.

HGH Fragment 176-191 is not an approved medicine for weight management, obesity, or metabolic disease in the United States or most other jurisdictions. It appears primarily in exploratory research discussions and in wellness products marketed around fat loss.

Because product quality, labeling accuracy, and regulatory status differ widely, any consideration of the fragment should be grounded in local regulations and a clear distinction between early exploratory research and established, evidence-based treatments for body weight or metabolism.

This is not a catch-all case. "hGH 176-191" appears verbatim as a named example on the WADA Prohibited List, in sub-section S2.2.3 covering growth hormone, its analogues and its fragments — the same bullet that names AOD-9604, which is the same 176-191 sequence with an added N-terminal tyrosine. Both are non-Specified Substances in S2, so the default sanction for a first violation is four years, and the prohibition runs year-round rather than in-competition only.

Naming matters here because the marketing claim for this fragment is that it splits GH's fat-mobilising effect away from its growth-promoting effect, and is therefore "not really growth hormone." The Prohibited List does not use that distinction: a fragment of GH is listed as a fragment of GH regardless of which downstream effects it retains.

Detection is also not theoretical. A published urine screening method for the closely related AOD-9604 reaches a limit of detection of 50 pg/mL and additionally targets a metabolite that is "significantly more stable than the other metabolites or the parent compound," specifically to widen the detection window (Cox et al., Drug Test Anal 2015).

Commonly discussed experiences include local injection-site reactions and nonspecific symptoms such as headache, fatigue, or gastrointestinal upset. Robust, long-term safety data across diverse populations are relatively sparse, and the purity of research-grade material can vary between suppliers.

As with other experimental peptides, careful attention to sourcing, regulatory guidance, and individual risk factors is important. High-level summaries cannot substitute for rigorous safety evaluation by a qualified clinician.

HGH Fragment 176-191 is a peptide corresponding to the C-terminal segment of human growth hormone. Its short half-life and peptide structure are frequently cited in discussions of how the compound behaves after administration, and it is the conceptual starting point for AOD-9604, a modified and stabilized analog of the same fragment.

Any decision about experimental peptides should account for the immaturity of the human evidence base and the absence of regulatory approval.

Three closely related names circulate for what are three different molecules, and the differences are small enough that vendors and buyers routinely conflate them:

• hGH 176-191 — the unmodified C-terminal fragment of human growth hormone. This page's subject.

• AOD-9604 — "a peptide consisting of the C-terminal fragment of human growth hormone from amino acids 177-191 with an additional tyrosine residue at the N-terminus" (Cox et al., Drug Test Anal 2015). A different span, plus an added residue — not a synonym. See AOD-9604.

• AOD-9401 — a different small synthetic hGH sequence, used in the oral rodent lipid-metabolism work often cited in support of this class (Heffernan et al., Am J Physiol Endocrinol Metab 2000).

The practical effect of the confusion is that evidence generated for one is quoted for another. It also has a regulatory dimension: AOD-9604 was nominated for the FDA's bulk drug substances lists and placed in the category of substances that may present significant safety risks, with the agency noting it "has identified no, or only limited, safety-related information" and "has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear" (FDA bulk drug substances page). That nomination was subsequently withdrawn by the party that submitted it.

Research on the growth hormone C-terminal fragment has examined its effects on fat metabolism and related markers, mostly in preclinical models and a limited number of human studies. Interest was driven by the appealing idea of isolating a "fat-loss" signal from growth hormone, but clinical fat-loss results have generally been underwhelming, and questions remain about effect size, study design, and reproducibility.

The best-known clinical development effort centered on AOD-9604, the stabilized analog, which did not deliver convincing weight-loss outcomes in later trials. Because the evidence base is mixed, claims about the fragment should be interpreted cautiously and are not a substitute for critical appraisal of primary data.

For deeper dives on this peptide, see:

• HGH Fragment 176-191 benefits and areas of interest
• HGH Fragment 176-191 side effects and safety context
• HGH Fragment 176-191 dosing concepts (educational)
• HGH Fragment 176-191 research and evidence overview
• AOD-9604 (stabilized analog of this fragment)

Is HGH Fragment 176-191 the same thing as AOD-9604? No, though they are close enough that the names get used interchangeably. AOD-9604 is "a peptide consisting of the C-terminal fragment of human growth hormone from amino acids 177-191 with an additional tyrosine residue at the N-terminus" (Cox et al., Drug Test Anal 2015) — a different residue span with an added amino acid. This matters because almost all of the clinical-development history people cite for "the fragment" belongs to AOD-9604, not to hGH 176-191.

Has anyone shown it causes fat loss in humans? No published trial reports that. PubMed indexes no completed clinical trial of hGH 176-191 with a body-composition endpoint, and ClinicalTrials.gov returns no studies for AOD-9604. What exists in the literature is the compound's appearance in obesity-pipeline reviews as a phase 2 candidate that never produced a published outcome (Wilding, Curr Opin Investig Drugs 2004; Halford 2006). A programme that reaches phase 2 and then goes quiet without publishing is not a neutral data point.

What is the actual supporting evidence, then? Rodent and ex-vivo work on a related sequence. Oral AOD-9401 in ob/ob mice slowed body weight gain from day 16 without changing food intake, reduced lipogenic and increased lipolytic activity in adipose tissue, and did the same in isolated adipose tissue from obese rodents and humans (Heffernan et al. 2000). Activity in a dish of human fat is a mechanistic result. It is not weight loss in a person.

Does it really avoid growth hormone's downsides? That is the hypothesis the whole compound was built on — separating GH's fat-mobilising effect from its growth-promoting and IGF-1 signalling — and it has never been confirmed by a controlled human study, because no such study has been published. The claim is also not accepted where it would matter most: anti-doping authorities list GH fragments as GH fragments regardless of which downstream effects they retain, as the anti-doping section above sets out.

Can a compounding pharmacy legally prepare it? The closest regulatory statement concerns AOD-9604, which FDA placed among bulk drug substances that may present significant safety risks, citing immunogenicity risk for certain routes, complexities with peptide-related impurities and API characterisation, "no, or only limited, safety-related information," and "serious adverse events that may be associated with AOD-9604, though causality is not clear" (FDA). The nomination was later withdrawn.

Can a laboratory detect it? Yes, and with a wide window. A validated urine method for AOD-9604 reaches a limit of detection of 50 pg/mL, and identifies a serum metabolite (amino acids CRSVEGSCG) that is "significantly more stable than the other metabolites or the parent compound," specifically so that screening can extend the detection window (Cox 2015).